Literature DB >> 7482004

An economic evaluation of schizophrenia--1991.

R J Wyatt1, I Henter, M C Leary, E Taylor.   

Abstract

In 1991, the costs for schizophrenia, which has a lifetime prevalence of 1.5% among adult Americans, totaled $65 billion. Costs were broken down into their direct and indirect components. Direct costs, which totaled $19 billion dollars, consisted of treatment-related expenditures such as those for inpatients and outpatients, as well as nontreatment-related expenditures such as those for the criminal justice system used by individuals with schizophrenia. The direct costs were fairly similar to those of other recent estimates of the cost of schizophrenia. Indirect costs, which were $46 billion dollars, included the lost productivity of both wage earners ($24 billion) and homemakers ($4.5 billion), individuals who were in institutions ($4.5 billion) or who had committed suicide ($7 billion), and caregivers who took care of schizophrenic family members ($7 billion). Our method for calculating the indirect costs was slightly different than methods used in prior studies, which may account for our estimates being higher. The method for determining each expenditure is provided, and the implications of these staggering costs are discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7482004      PMCID: PMC4300526          DOI: 10.1007/BF00789054

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  22 in total

1.  The cost of schizophrenia.

Authors:  J G Gunderson; L R Mosher
Journal:  Am J Psychiatry       Date:  1975-09       Impact factor: 18.112

Review 2.  Depression, attempted suicide, and suicide in patients with chronic schizophrenia.

Authors:  A Roy
Journal:  Psychiatr Clin North Am       Date:  1986-03

3.  Prevalence of treated and untreated DSM-III schizophrenia. Results of a two-stage community survey.

Authors:  M Von Korff; G Nestadt; A Romanoski; J Anthony; W Eaton; A Merchant; R Chahal; M Kramer; M Folstein; E Gruenberg
Journal:  J Nerv Ment Dis       Date:  1985-10       Impact factor: 2.254

4.  Characteristics of community support program clients in 1980 and 1984.

Authors:  V M Mulkern; R W Manderscheid
Journal:  Hosp Community Psychiatry       Date:  1989-02

5.  Risk factors for homelessness among schizophrenic men: a case-control study.

Authors:  C L Caton; P E Shrout; P F Eagle; L A Opler; A Felix; B Dominguez
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

6.  Cost measurement and cost data in mental health settings.

Authors:  J Rubin
Journal:  Hosp Community Psychiatry       Date:  1982-09

7.  Mental health cost models. Refinements and applications.

Authors:  B Dickey; T G McGuire; N L Cannon; J E Gudeman
Journal:  Med Care       Date:  1986-09       Impact factor: 2.983

8.  The prevalence of severe mental disorder among male urban jail detainees: comparison with the Epidemiologic Catchment Area Program.

Authors:  L A Teplin
Journal:  Am J Public Health       Date:  1990-06       Impact factor: 9.308

9.  What do police officers really want from the mental health system?

Authors:  P M Gillig; M Dumaine; J W Stammer; J R Hillard; P Grubb
Journal:  Hosp Community Psychiatry       Date:  1990-06

10.  The economic costs of schizophrenia. Implications for public policy.

Authors:  G Andrews; W Hall; G Goldstein; H Lapsley; R Bartels; D Silove
Journal:  Arch Gen Psychiatry       Date:  1985-06
View more
  41 in total

1.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

2.  Cost effectiveness of long-acting risperidone: what can pharmacoeconomic models teach us?

Authors:  Lieven Annemans
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models.

Authors:  Alan Haycox
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Performance-based measures of functional skills: usefulness in clinical treatment studies.

Authors:  Philip D Harvey; Dawn I Velligan; Alan S Bellack
Journal:  Schizophr Bull       Date:  2007-05-09       Impact factor: 9.306

Review 5.  [Therapeutic drug monitoring in epileptology and psychiatry].

Authors:  C Brandt; P Baumann; G Eckermann; C Hiemke; T W May; B Rambeck; B Pohlmann-Eden
Journal:  Nervenarzt       Date:  2008-02       Impact factor: 1.214

Review 6.  The burden of mental disorders.

Authors:  William W Eaton; Silvia S Martins; Gerald Nestadt; O Joseph Bienvenu; Diana Clarke; Pierre Alexandre
Journal:  Epidemiol Rev       Date:  2008-09-19       Impact factor: 6.222

7.  Reducing emergency medical service use in patients with chronic psychotic disorders: results from the FAST intervention study.

Authors:  Brent T Mausbach; Veronica Cardenas; Christine L McKibbin; Dilip V Jeste; Thomas L Patterson
Journal:  Behav Res Ther       Date:  2007-10-07

8.  Factors associated with emotional distress among caregivers of patients with schizophrenia in Katsina, Nigeria.

Authors:  Abdulkareem Jika Yusuf; Folorunsho Tajudeen Nuhu
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-11-12       Impact factor: 4.328

Review 9.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 10.  Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?

Authors:  Christoph Hiemke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.